Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Dow
Fish and Richardson
McKesson
Novartis
Accenture
Colorcon
Farmers Insurance
US Department of Justice
Argus Health

Generated: February 20, 2018

DrugPatentWatch Database Preview

SORILUX Drug Profile

« Back to Dashboard

When do Sorilux patents expire, and what generic alternatives are available?

Sorilux is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-six patent family members in twelve countries.

The generic ingredient in SORILUX is calcipotriene. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.
Summary for SORILUX
International Patents:26
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 64
Clinical Trials: 1
Patent Applications: 4,019
Drug Prices:see details
DailyMed Link:SORILUX at DailyMed
Drug patent expirations by year for SORILUX
Pharmacology for SORILUX
Ingredient-typeVitamin D
Drug ClassVitamin D Analog

US Patents and Regulatory Information for SORILUX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for SORILUX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,730,288 Mousse composition ➤ Try a Free Trial
7,029,659 Mousse composition ➤ Try a Free Trial
8,298,515 Vitamin formulation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for SORILUX

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
AstraZeneca
Express Scripts
McKinsey
Farmers Insurance
Cipla
UBS
Cantor Fitzgerald
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot